Clinical trials for Essential thrombocythemia
38 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG · PI: Konstanze Döhner, Prof. Dr. med.
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · PI: TIZIANO BARBUI, MD
- RECRUITINGPhase 2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGN/ANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong · PI: ZhenYa Hong, Ph.D
- RECRUITINGPhase 1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc. · PI: John Mascarenhas, M.D.
- RECRUITINGPhase 2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai · PI: John Mascarenhas
- RECRUITINGPhase 2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd. · PI: Lei Zhang
- RECRUITINGPHASE1, PHASE2NCT06327100Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)M.D. Anderson Cancer Center · PI: Lucia Masarova, MD
- RECRUITINGPhase 3NCT06456346Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGN/ANCT06361641Functional and Phenotypic Characterization of Monocytes in Myeloproliferative SyndromesUniversity Hospital, Angers · PI: Agathe GOUBAND, PharmD
- RECRUITINGPhase 3NCT06351631A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPhase 2NCT06063486Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative NeoplasmsUniversity of Southern California · PI: Casey L O'Connell, MD
- RECRUITINGPhase 3NCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPhase 2NCT05835466Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Icahn School of Medicine at Mount Sinai · PI: Marina Kremyanskaya, PhD, MD
- RECRUITINGNCT06073847A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With MyelofibrosisBristol-Myers Squibb · PI: Bristol-Myers Squibb
- RECRUITINGNCT05440838Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.University Hospital, Angers
- RECRUITINGNCT05882773Asian Myeloproliferative Neoplasm (MPN) RegistryThe University of Hong Kong · PI: Harinder Gill, MD
- RECRUITINGPhase 1NCT05025488Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative NeoplasmMarina Kremyanskaya · PI: Marina Kremyanskaya, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT05482971A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ETPharmaEssentia · PI: Oleh Zagrijtschuk, MD, PhD
- RECRUITINGPhase 2NCT05467800Study of Canakinumab in Patients With MyelofibrosisJohn Mascarenhas · PI: John Mascarenhas, MD
- RECRUITINGPhase 3NCT05198960AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative NeoplasmsUniversity Hospital, Brest
- RECRUITINGPHASE1, PHASE2NCT05320198Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaDisc Medicine, Inc · PI: Will Savage, MD PhD
- RECRUITINGNCT06516406Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia VeraIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPhase 2NCT04644211Ruxolitinib in Thrombocythemia and Polycythemia VeraMassachusetts General Hospital · PI: Gabriela Hobbs, MD
- ACTIVE NOT RECRUITINGNCT06798805Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative NeoplasmsIRCCS Azienda Ospedaliero-Universitaria di Bologna · PI: Lucia Catani, MD
- RECRUITINGPHASE1, PHASE2NCT05123365An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative NeoplasmsUniversity of California, Irvine · PI: Angela Fleischman, MD, PhD
- RECRUITINGN/ANCT04942080Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)University Hospital, Angers
- ACTIVE NOT RECRUITINGPhase 3NCT04603495Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04455841INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersIncyte Corporation · PI: Amanda McBride, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04517851Elotuzumab for the Treatment of JAK2-Mutated MyelofibrosisM.D. Anderson Cancer Center · PI: Prithviraj Bose
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04446650A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Bristol-Myers Squibb · PI: Bristol Myers Squibb
- ACTIVE NOT RECRUITINGPhase 2NCT04262141IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)Terrence J Bradley, MD · PI: Terrence J Bradley, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04285086Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntolerancePharmaEssentia · PI: Toshiaki Sato, MD/PhD
- ACTIVE NOT RECRUITINGPhase 2NCT04081220Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2The University of Texas Health Science Center at San Antonio · PI: Zohra Nooruddin, MD
- RECRUITINGPhase 2NCT04226950Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential ThrombocythemiaInstitute of Hematology & Blood Diseases Hospital, China · PI: Lei Zhang, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03441113Extended Access of Momelotinib in Adults With MyelofibrosisGlaxoSmithKline · PI: GSK Clinical Trials
- RECRUITINGNCT02897297Myeloproliferative Neoplastic Diseases Observatory From BrestUniversity Hospital, Brest · PI: Jean-Christophe Ianotto